Terry Hermiston

Dr. Hermiston has over 20 years of industrial experience in research and drug development. His experience in research and drug development is mainly focused on idea conception and concept validation, making his role in leadership and advisory positions of emerging biotechnology companies invaluable. Dr. Hermiston is currently the Chief Executive Officer of Coagulant Therapeutics and GLAdiator Biosciences.

Dr. Hermiston previously served as the VP of Biologics Research in the US and Site Head of Bayer Healthcare’s US Innovation Center, where he managed research teams both locally and globally, co-chairing the company’s early research portfolio in hematology, immuno-oncology, and antibody-drug conjugate programs. Prior to joining Bayer, Dr. Hermiston was heavily involved in the research and development around early-generation oncolytic virus programs at both Berlex Biosciences and Onyx Pharmaceuticals. Notably at Berlex, Dr. Hermiston and his team created a novel oncolytic virus ColoAd1 (enadenotucirev), which is currently in Phase II clinical trials and eventually became the foundation to a near $1 billion partnership with Bristol-Myers Squibb.